Genetics of Alcoholic Liver Disease

Seminars in Liver Disease

Volumn 35, Issue 4, 2015, Pages 361-374

  Anstee, Quentin M ^a   Daly, Ann K ^a   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

alcoholic liver disease; gene; polymorphism; steatohepatitis

Indexed keywords

CYTOKINE; ENDOTOXIN; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; ALCOHOL; MEMBRANE PROTEIN; TLR4 PROTEIN, HUMAN; TM6SF2 PROTEIN, HUMAN; TRIACYLGLYCEROL LIPASE;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ANIMAL EXPERIMENT; ARTICLE; DISEASE COURSE; DNA MODIFICATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HIGH RISK BEHAVIOR; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); ALCOHOL LIVER CIRRHOSIS; ALCOHOLIC FATTY LIVER; ALCOHOLISM; DRINKING BEHAVIOR; GENETIC POLYMORPHISM; GENOME-WIDE ASSOCIATION STUDY; IMMUNITY; LIVER TUMOR; METABOLISM; PHENOTYPE; SYNAPTIC TRANSMISSION;

ALCOHOL DRINKING; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ETHANOL; FATTY LIVER, ALCOHOLIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY; LIPASE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MEMBRANE PROTEINS; OXIDATIVE STRESS; PHENOTYPE; POLYMORPHISM, GENETIC; SYNAPTIC TRANSMISSION; TOLL-LIKE RECEPTOR 4;

EID: 84949967608     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1567832     Document Type: Article

References (163)

1. Rehm J., Samokhvalov A. V., Shield K. D. Global burden of alcoholic liver diseases. J Hepatol: 2013; 59 1 160 168
2. Teli M. R., Day C. P., Burt A. D., Bennett M. K., James O. F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet: 1995; 346 8981 987 990
3. Anstee Q. M., Targher G., Day C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol: 2013; 10 6 330 344
4. Lieber C. S., Jones D. P., Decarli L. M. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest: 1965; 44 1009 1021
5. Lieber C. S., Decarli L. M. Animal models of ethanol dependence and liver injury in rats and baboons. Fed Proc: 1976; 35 5 1232 1236
6. Brandon-Warner E., Schrum L. W., Schmidt C. M., McKillop I. H. Rodent models of alcoholic liver disease: of mice and men. Alcohol: 2012; 46 8 715 725
7. Bellentani S., Saccoccio G., Costa G., et al. The Dionysos Study Group. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut: 1997; 41 6 845 850
8. Becker U., Deis A., Sorensen T. I., et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology: 1996; 23 5 1025 1029
9. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology: 1997; 112 2 463 472
10. Anstee Q. M., Daly A. K., Day C. P. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis: 2011; 31 2 128 146
11. Askgaard G., Gronbæk M., Kjær M. S., Tjonneland A., Tolstrup J. S. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol: 2015; 62 5 1061 1067
12. Naveau S., Giraud V., Borotto E., Aubert A., Capron F., Chaput J. C. Excess weight risk factor for alcoholic liver disease. Hepatology: 1997; 25 1 108 111
13. Becker U., Gronbaek M., Johansen D., Sorensen T. I. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology: 2002; 35 4 868 875
14. Johansen D., Friis K., Skovenborg E., Gronbaek M. Food buying habits of people who buy wine or beer: cross sectional study. BMJ: 2006; 332 7540 519 522
15. Rotily M., Durbec J. P., Berthézène P., Sarles H. Diet and alcohol in liver cirrhosis: a case-control study. Eur J Clin Nutr: 1990; 44 8 595 603
16. Iturriaga H., Bunout D., Hirsch S., Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr: 1988; 47 2 235 238
17. Liu B., Balkwill A., Reeves G., Beral V.; Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ: 2010; 340 c912
18. Hart C. L., Morrison D. S., Batty G. D., Mitchell R. J., Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ: 2010; 340 c1240
19. Sanyal A. J.; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology: 2002; 123 5 1705 1725
20. Marchesini G., Brizi M., Morselli-Labate A. M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med: 1999; 107 5 450 455
21. Powell E. E., Cooksley W. G., Hanson R., Searle J., Halliday J. W., Powell L. W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology: 1990; 11 1 74 80
22. Raynard B., Balian A., Fallik D., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology: 2002; 35 3 635 638
23. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet: 1997; 349 9055 825 832
24. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol: 2001; 34 5 730 739
25. [Anonymous] International HapMap Consortium A haplotype map of the human genome. Nature: 2005; 437 7063 1299 1320
26. Frazer K. A., Ballinger D. G., Cox D. R., et al. International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature: 2007; 449 7164 851 861
27. Manolio T. A., Brooks L. D., Collins F. S. A HapMap harvest of insights into the genetics of common disease. J Clin Invest: 2008; 118 5 1590 1605
28. Hardy J., Singleton A. Genomewide association studies and human disease. N Engl J Med: 2009; 360 17 1759 1768
29. Hirschhorn J. N., Daly M. J. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet: 2005; 6 2 95 108
30. Anstee Q., Day C. The genetics of non-alcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis: 2015; 35 3 270 290
31. Agrawal A., Bierut L. J. Identifying genetic variation for alcohol dependence. Alcohol Res: 2012; 34 3 274 281
32. Buch S., Stickel F., Trepo E., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet: 2015;; in press
33. Whitfield J. B., Rahman K., Haber P. S., et al. GenomALC Consortium. Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. Alcohol Clin Exp Res: 2015; 39 5 836 842
34. Nolan P. M., Peters J., Strivens M., et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet: 2000; 25 4 440 443
35. Waterston R. H., Lindblad-Toh K., Birney E., et al. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature: 2002; 420 6915 520 562
36. Gama Sosa M. A., De Gasperi R., Elder G. A. Animal transgenesis: an overview. Brain Struct Funct: 2010; 214 2-3 91 109
37. Doudna J. A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science: 2014; 346 6213 1258096
38. Shalem O., Sanjana N. E., Zhang F. High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet: 2015; 16 5 299 311
39. Acevedo-Arozena A., Wells S., Potter P., Kelly M., Cox R. D., Brown S. D. ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet: 2008; 9 49 69
40. Anstee Q. M., Knapp S., Maguire E. P., et al. Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition. Nat Commun: 2013; 4 2816
41. Grant B. F., Dawson D. A., Stinson F. S., Chou S. P., Dufour M. C., Pickering R. P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend: 2004; 74 3 223 234
42. Bierut L. J., Dinwiddie S. H., Begleiter H., et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch Gen Psychiatry: 1998; 55 11 982 988
43. Midanik L. Familial alcoholism and problem drinking in a national drinking practices survey. Addict Behav: 1983; 8 2 133 141
44. Agrawal A., Lynskey M. T. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction: 2008; 103 7 1069 1081
45. Enoch M. A. The role of GABA(A) receptors in the development of alcoholism. Pharmacol Biochem Behav: 2008; 90 1 95 104
46. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet: 2005; 6 7 521 532
47. McCarthy M. I., Hirschhorn J. N. Genome-wide association studies: potential next steps on a genetic journey. Hum Mol Genet: 2008; 17 (R2): R156 R165
48. Barnard E. A., Skolnick P., Olsen R. W., et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev: 1998; 50 2 291 313
49. Long J. C., Knowler W. C., Hanson R. L., et al. Evidence for genetic linkage to alcohol dependence on chromosomes 4 and 11 from an autosome-wide scan in an American Indian population. Am J Med Genet: 1998; 81 3 216 221
50. Williams J. T., Begleiter H., Porjesz B., et al. Joint multipoint linkage analysis of multivariate qualitative and quantitative traits. II. Alcoholism and event-related potentials. Am J Hum Genet: 1999; 65 4 1148 1160
51. Reich T., Edenberg H. J., Goate A., et al. Genome-wide search for genes affecting the risk for alcohol dependence. Am J Med Genet: 1998; 81 3 207 215
52. Porjesz B., Almasy L., Edenberg H. J., et al. Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proc Natl Acad Sci U S A: 2002; 99 6 3729 3733
53. Zinn-Justin A., Abel L. Genome search for alcohol dependence using the weighted pairwise correlation linkage method: interesting findings on chromosome 4. Genet Epidemiol: 1999; 17 01 S421 S426
54. Ghosh S., Begleiter H., Porjesz B., et al. Linkage mapping of beta 2 EEG waves via non-parametric regression. Am J Med Genet B Neuropsychiatr Genet: 2003; 118B 1 66 71
55. Edenberg H. J., Dick D. M., Xuei X., et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet: 2004; 74 4 705 714
56. Agrawal A., Edenberg H. J., Foroud T., et al. Association of GABRA2 with drug dependence in the collaborative study of the genetics of alcoholism sample. Behav Genet: 2006; 36 5 640 650
57. Covault J., Gelernter J., Hesselbrock V., Nellissery M., Kranzler H. R. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet: 2004; 129B 1 104 109
58. Lappalainen J., Krupitsky E., Remizov M., et al. Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res: 2005; 29 4 493 498
59. Fehr C., Sander T., Tadic A., et al. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet: 2006; 16 1 9 17
60. Bauer L. O., Covault J., Harel O., et al. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res: 2007; 31 11 1780 1787
61. Pierucci-Lagha A., Covault J., Feinn R., et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology: 2005; 30 6 1193 1203
62. Parsian A., Zhang Z. H. Human chromosomes 11p15 and 4p12 and alcohol dependence: possible association with the GABRB1 gene. Am J Med Genet: 1999; 88 5 533 538
63. Song J., Koller D. L., Foroud T., et al. Association of GABA(A) receptors and alcohol dependence and the effects of genetic imprinting. Am J Med Genet B Neuropsychiatr Genet: 2003; 117B 1 39 45
64. Enoch M. A., Schwartz L. S., White K. V., et al. Linkage of GABRB1 to alcoholism and low voltage ALPHA EEG in two independent populations. Alcohol Clin Exp Res: 2005; 29 5 132a
65. Dick D. M., Bierut L. J. The genetics of alcohol dependence. Curr Psychiatry Rep: 2006; 8 2 151 157
66. Whitfield J. B., Nightingale B. N., Bucholz K. K., Madden P. A., Heath A. C., Martin N. G. ADH genotypes and alcohol use and dependence in Europeans. Alcohol Clin Exp Res: 1998; 22 7 1463 1469
67. McCarver D. G., Thomasson H. R., Martier S. S., Sokol R. J., Li T. Alcohol dehydrogenase-2∗3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther: 1997; 283 3 1095 1101
68. Köhnke M. D. Approach to the genetics of alcoholism: a review based on pathophysiology. Biochem Pharmacol: 2008; 75 1 160 177
69. Zintzaras E., Stefanidis I., Santos M., Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology: 2006; 43 2 352 361
70. Harada S., Agarwal D. P., Goedde H. W., Tagaki S., Ishikawa B. Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan. Lancet: 1982; 2 8302 827
71. Sato N., Lindros K. O., Baraona E., et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res: 2001; 25 (5, Suppl ISBRA) 40S 45S
72. Stinson F. S., Grant B. F., Dufour M. C. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res: 2001; 25 8 1181 1187
73. Reed T., Page W. F., Viken R. J., Christian J. C. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res: 1996; 20 9 1528 1533
74. Hrubec Z., Omenn G. S. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res: 1981; 5 2 207 215
75. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet: 2008; 40 12 1461 1465
76. Sookoian S., Castaño G. O., Burgueño A. L., Gianotti T. F., Rosselli M. S., Pirola C. J. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res: 2009; 50 10 2111 2116
77. Rotman Y., Koh C., Zmuda J. M., Kleiner D. E., Liang T. J.; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology: 2010; 52 3 894 903
78. Valenti L., Al-Serri A., Daly A. K., et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology: 2010; 51 4 1209 1217
79. Singal A. G., Manjunath H., Yopp A. C., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol: 2014; 109 3 325 334
80. Liu Y. L., Patman G. L., Leathart J. B., et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol: 2014; 61 1 75 81
81. Anstee Q. M., Day C. P. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol: 2013; 10 11 645 655
82. Salameh H., Raff E., Erwin A., et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol: 2015; 110 6 846 856
83. Romeo S., Huang-Doran I., Baroni M. G., Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol: 2010; 21 3 247 252
84. Zimmermann R., Strauss J. G., Haemmerle G., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science: 2004; 306 5700 1383 1386
85. Rydel T. J., Williams J. M., Krieger E., et al. The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad. Biochemistry: 2003; 42 22 6696 6708
86. He S., McPhaul C., Li J. Z., et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem: 2010; 285 9 6706 6715
87. Speliotes E. K., Yerges-Armstrong L. M., Wu J., et al. NASH CRN; GIANT Consortium; MAGIC Investigators; GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet: 2011; 7 3 e1001324
88. Kozlitina J., Smagris E., Stender S., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet: 2014; 46 4 352 356
89. Liu Y. L., Reeves H. L., Burt A. D., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun: 2014; 5 4309
90. Dongiovanni P., Petta S., Maglio C., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology: 2015; 61 2 506 514
91. Way M., Atkinson S., McQuillin A., et al. A functional variant in TM6SF2 associates with alcohol related cirrhosis risk in a British and Irish population. J Hepatol: 2015; 62 S772
92. Nagata K., Suzuki H., Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci: 2007; 32 5 453 468
93. Wu D., Cederbaum A. I. Oxidative stress and alcoholic liver disease. Semin Liver Dis: 2009; 29 2 141 154
94. Mandrekar P., Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol: 2009; 50 6 1258 1266
95. Malhi H., Gores G. J., Lemasters J. J. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology: 2006; 43 2 01 S31 S44
96. Anstee Q. M., Concas D., Kudo H., et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol: 2010; 53 3 542 550
97. Farrell G. C., Larter C. Z., Hou J. Y., et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol: 2009; 24 3 443 452
98. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest: 2007; 117 3 539 548
99. Zeng T., Guo F. F., Zhang C. L., Song F. Y., Zhao X. L., Xie K. Q. Roles of cytochrome P4502E1 gene polymorphisms and the risks of alcoholic liver disease: a meta-analysis. PLoS ONE: 2013; 8 1 e54188
100. Grove J., Daly A. K., Burt A. D., et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut: 1998; 43 2 262 266
101. Gleeson D., Evans S., Bradley M., et al. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am J Gastroenterol: 2006; 101 2 304 310
102. Macmillan-Crow L. A., Cruthirds D. L. Invited review: manganese superoxide dismutase in disease. Free Radic Res: 2001; 34 4 325 336
103. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawa-Hattori Y., Shimizu Y., Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun: 1996; 226 2 561 565
104. Sutton A., Imbert A., Igoudjil A., et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics: 2005; 15 5 311 319
105. Sutton A., Khoury H., Prip-Buus C., Cepanec C., Pessayre D., Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics: 2003; 13 3 145 157
106. Namikawa C., Shu-Ping Z., Vyselaar J. R., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol: 2004; 40 5 781 786
107. Al-Serri A., Anstee Q. M., Valenti L., et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol: 2011; 56 2 448 454
108. Degoul F., Sutton A., Mansouri A., et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology: 2001; 120 6 1468 1474
109. Stewart S. F., Leathart J. B., Chen Y., et al. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology: 2002; 36 6 1355 1360
110. Martins A., Cortez-Pinto H., Machado M., et al. Are genetic polymorphisms of tumour necrosis factor alpha, interleukin-10, CD14 endotoxin receptor or manganese superoxide dismutase associated with alcoholic liver disease? Eur J Gastroenterol Hepatol: 2005; 17 10 1099 1104
111. Nahon P., Sutton A., Rufat P., et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology: 2009; 50 5 1484 1493
112. Buch S., Schafmayer C., Völzke H., et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet: 2007; 39 8 995 999
113. Ladero J. M., Martínez C., García-Martin E., et al. Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease. Scand J Gastroenterol: 2005; 40 3 348 353
114. Brind A. M., Hurlstone A., Edrisinghe D., et al. The role of polymorphisms of glutathione S-transferases GSTM1, M3, P1, T1 and A1 in susceptibility to alcoholic liver disease. Alcohol Alcohol: 2004; 39 6 478 483
115. Hubatsch I., Ridderström M., Mannervik B. Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem J: 1998; 330 (Pt 1): 175 179
116. Quigley E. M., Monsour H. P. The gut microbiota and non-alcoholic fatty liver disease. Semin Liver Dis: 2015; 35 3 262 269
117. Baldini M., Lohman I. C., Halonen M., Erickson R. P., Holt P. G., Martinez F. D. A Polymorphism∗ in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol: 1999; 20 5 976 983
118. Järveläinen H. A., Orpana A., Perola M., Savolainen V. T., Karhunen P. J., Lindros K. O. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology: 2001; 33 5 1148 1153
119. Campos J., Gonzalez-Quintela A., Quinteiro C., et al. The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers. Alcohol Clin Exp Res: 2005; 29 7 1206 1213
120. Meiler C., Muhlbauer M., Johann M., et al. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol: 2005; 11 38 6031 6037
121. Leathart J. B., Day C. P., Daly A. K. No association between functional SNPs in the endotoxin receptors CD14 and TLR4 and alcoholic liver disease (ALD): Is endotoxin important in the pathogenesis of aid in humans? Hepatology: 2001; 34 459a
122. Arbour N. C., Lorenz E., Schutte B. C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet: 2000; 25 2 187 191
123. Zeng T., Zhang C. L., Han X. Y., Zhao S., Xie K. Q. Association between CD14-159C>T polymorphisms and the risk for alcoholic liver disease: a meta-analysis. Eur J Gastroenterol Hepatol: 2013; 25 10 1183 1189
124. Grove J., Daly A. K., Bassendine M. F., Gilvarry E., Day C. P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut: 2000; 46 4 540 545
125. Lazarus R., Klimecki W. T., Palmer L. J., et al. Single-nucleotide polymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics: 2002; 80 2 223 228
126. Ladero J. M., Fernández-Arquero M., Tudela J. I., et al. Single nucleotide polymorphisms and microsatellite alleles of tumor necrosis factor alpha and interleukin-10 genes and the risk of advanced chronic alcoholic liver disease. Liver: 2002; 22 3 245 251
127. Roy N., Mukhopadhyay I., Das K., et al. Genetic variants of TNFα, IL10, IL1β, CTLA4 and TGFβ1 modulate the indices of alcohol-induced liver injury in East Indian population. Gene: 2012; 509 1 178 188
128. Takamatsu M., Yamauchi M., Maezawa Y., Saito S., Maeyama S., Uchikoshi T. Genetic polymorphisms of interleukin-1beta in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol: 2000; 95 5 1305 1311
129. McClain C., Hill D., Schmidt J., Diehl A. M. Cytokines and alcoholic liver disease. Semin Liver Dis: 1993; 13 2 170 182
130. Grove J., Daly A. K., Bassendine M. F., Day C. P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology: 1997; 26 1 143 146
131. Pastor I. J., Laso F. J., Romero A., González-Sarmiento R. -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res: 2005; 29 11 1928 1931
132. Wilfred de Alwis N. M., Day C. P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis: 2007; 27 1 44 54
133. Marcos M., Gómez-Munuera M., Pastor I., González-Sarmiento R., Laso F. J. Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. Am J Epidemiol: 2009; 170 8 948 956
134. Oakley F., Teoh V., Ching-A-Sue G., et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology: 2009; 136 7 2334 2344.e1
135. Marcos M., Pastor I., González-Sarmiento R., Laso F. J. A functional polymorphism of the NFKB1 gene increases the risk for alcoholic liver cirrhosis in patients with alcohol dependence. Alcohol Clin Exp Res: 2009; 33 11 1857 1862
136. Osterreicher C. H., Halangk J., Berg T., et al. Evaluation of the transforming growth factor beta1 codon 25 (Arg->Pro) polymorphism in alcoholic liver disease. Cytokine: 2008; 42 1 18 23
137. Stickel F., Osterreicher C. H., Halangk J., et al. No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res: 2008; 32 6 959 965
138. Bashir R., Day C. P., James O. F., Ogilvie D. J., Sykes B., Bassendine M. F. No evidence for involvement of type 1 collagen structural genes in 'genetic predisposition' to alcoholic cirrhosis. J Hepatol: 1992; 16 3 316 319
139. Sutton A., Nahon P., Pessayre D., et al. Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res: 2006; 66 5 2844 2852
140. Nahon P., Sutton A., Pessayre D., et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol: 2005; 3 3 292 298
141. Saffroy R., Pham P., Chiappini F., et al. The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis: 2004; 25 8 1443 1448
142. Hassan M. M., Kaseb A., Etzel C. J., et al. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog: 2013; 52 01 E139 E147
143. Burza M. A., Pirazzi C., Maglio C., et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis: 2012; 44 12 1037 1041
144. Guyot E., Sutton A., Rufat P., et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol: 2013; 58 2 312 318
145. Nischalke H. D., Berger C., Luda C., et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS ONE: 2011; 6 11 e27087
146. Valenti L., Rumi M., Galmozzi E., et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology: 2011; 53 3 791 799
147. Falleti E., Fabris C., Cmet S., et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int: 2011; 31 8 1137 1143
148. Trépo E., Nahon P., Bontempi G., et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology: 2014; 59 6 2170 2177
149. Trepo E., Guyot E., Ganne-Carrie N., et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology: 2012; 55 4 1307 1308
150. Nischalke H. D., Lutz P., Krämer B., et al. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. J Hepatol: 2014; 61 5 1073 1079
151. Anstee Q. M., Liu Y. L., Day C. P., Reeves H. L. Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. J Hepatol: 2015; 62 4 982 983
152. Manolio T. A. Bringing genome-wide association findings into clinical use. Nat Rev Genet: 2013; 14 8 549 558
153. Anstee Q. M., Day C. P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol: 2012; 57 5 1097 1109
154. Molina P. E. Alcohol-intoxicating roadblocks and bottlenecks in hepatic protein and lipid metabolism. Am J Physiol Endocrinol Metab: 2008; 295 1 E1 E2
155. Tian C., Stokowski R. P., Kershenobich D., Ballinger D. G., Hinds D. A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet: 2010; 42 1 21 23
156. Seth D., Daly A. K., Haber P. S., Day C. P. Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology: 2010; 51 4 1463 1465
157. Stickel F., Buch S., Lau K., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology: 2011; 53 1 86 95
158. Trépo E., Gustot T., Degré D., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol: 2011; 55 4 906 912
159. Nguyen-Khac E., Houchi H., Dreher M. L., et al. Is pnpla3 polymorphism involved in severe acute alcoholic hepatitis. Hepatology: 2011; 54 976a
160. Rosendahl J., Tönjes A., Schleinitz D., et al. A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS ONE: 2012; 7 1 e29433
161. Dutta A. K. Genetic factors affecting susceptibility to alcoholic liver disease in an Indian population. Ann Hepatol: 2013; 12 6 901 907
162. Burza M. A., Molinaro A., Attilia M. L., et al. PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int: 2014; 34 4 514 520
163. Way M. J., McQuillin A., Gurling H. MD., et al. The Pnpa3 I148m mutation significantly increases the risk of developing alcohol-related cirrhosis in alcohol dependent individuals. J Hepatol: 2013; 58 S563 S564